Table of Contents

company-logo

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Inovio Pharmaceuticals Dividend Announcement

• Inovio Pharmaceuticals announced a quarterly dividend of $0.01 per ordinary share which will be made payable on 2017-10-16. Ex dividend date: 2017-09-28
• Inovio Pharmaceuticals's trailing twelve-month (TTM) dividend yield is -%

Inovio Pharmaceuticals Dividend History

Ex-Div dateDividend amountDividend typePay date
2017-09-28$0.01quarterly2017-10-16
2017-08-29$0.01quarterly2017-09-15
2017-07-27$0.01quarterly2017-08-15
2017-06-28$0.01quarterly2017-07-17

Inovio Pharmaceuticals Dividend per year

Inovio Pharmaceuticals Dividend Yield

Inovio Pharmaceuticals current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Inovio Pharmaceuticals stock? Use our calculator to estimate your expected dividend yield:

Inovio Pharmaceuticals Financial Ratios

P/E ratio-1.19
PEG ratio0.06
P/B ratio1.50
ROE-108.93%
Payout ratio0.00%
Current ratio4.45
Quick ratio4.45
Cash Ratio1.30

Inovio Pharmaceuticals Dividend FAQ

Does Inovio Pharmaceuticals stock pay dividends?
Inovio Pharmaceuticals does not currently pay dividends to its shareholders.
Has Inovio Pharmaceuticals ever paid a dividend?
No, Inovio Pharmaceuticals has no a history of paying dividends to its shareholders. Inovio Pharmaceuticals is not known for its dividend payments.
Why doesn't Inovio Pharmaceuticals pay dividends?
There are several potential reasons why Inovio Pharmaceuticals would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Inovio Pharmaceuticals ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Inovio Pharmaceuticals has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Inovio Pharmaceuticals a dividend aristocrat?
Inovio Pharmaceuticals is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Inovio Pharmaceuticals a dividend king?
Inovio Pharmaceuticals is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Inovio Pharmaceuticals a dividend stock?
No, Inovio Pharmaceuticals is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Inovio Pharmaceuticals stocks?
To buy Inovio Pharmaceuticals you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Inovio Pharmaceuticals stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.